Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd.

Tian Tang

Jing Wu

Jin Wang

Hanlin Feng

Yanqing Wang

Lin Yu

Tao Shi

Jing'an Yang

Feng Jin

Xiaorou Liu

Shenglin Luan

Yidong Feng

Hanmin Huang

Xiarou Liu

Ruyi Jin

Yanping Chen

Zhiying Huang

The present invention relates to a multi-target tyrosine kinase inhibitor, which is a compound having protein kinase inhibitory activity as shown in formula (I). The compound is metabolized into an active small molecule td32-4 that inhibits tumor growth in vivo, so as to achieve the anti-tumor effect. Compared with td32-4, the compound of the present invention has significantly improved solubility and oral bioavailability, and shows strong anti-tumor activity in animal in vivo experiments. The present invention relates to a synthetic method for the compound of formula (I) and an application thereof in the field of pharmaceuticals.

Multi-target tyrosine kinase inhibitor

Provided in the present invention are a crystal form of a small molecule immune compound, a preparation method therefor and a pharmaceutical composition containing the same; the compound is (3Z,6Z)-3-[((E)-3-(5-tert-butyl)-1H-imidazolyl-4-yl)methylene]-6-((E)-3-(3-fluorophenyl)-2-propenylene)piperazine-2,5-dione; the crystal form thereof has stable morphology, good chemical stability, high temperature resistance, and is used for treating hyperproliferative diseases. The structural formula of the compound is as shown in formula (I). 

Crystal form of small molecule immune compound, preparation method thereof and pharmaceutical composition containing the same

Provided are a new tubulin inhibitor and applications thereof, the tubulin inhibitor being a series of compounds based on substituted heterocyclic skeletons, targeting the colchicine binding sites of tubulin. The structure is: Formula (I), wherein: formula (A), n independently expresses an integer between 0 and 5, the condition being that n&#x2264;5, A represents mono- or poly-substituted groups, the groups being selected from the group consisting of H, C1-C20 amide group, C1-C20 acyloxy group, C1-C20 alkanoyl group, C1-C20 alkoxycarbonyl group, C1-C20 alkoxy group, C1-C20 alkylamino group, C1-C20 alkylcarboxyamino group, aroyl group, aralkanoyl group, carboxyl group, cyano group, halogen group, hydroxyl group, nitro group and methylthienyl group. 

Tubulin inhibitor

Provided is a composition of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(ethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide p-toluene sulfonate 1.5 hydrate &#x3b1;-polymorph. The &#x3b1;-polymorph has a stable form, a defined melting point, a good chemical stability, and a good endurance to high temperature and light irradiation, and is suitable for pharmaceutical use.

Crystal form of neptinib di-p-methylbenzenesulfonate, preparation method thereof, and pharmaceutical composition containing same

Growing community of inventors

Guangdong, China

Tian Tang